ライフサイエンスコーパス: at a dose of

1 f fitusiran administered either once weekly (at a dose of 0.015, 0.045, or 0.075 mg per kilogram) or

2 in FR104 recipients and was already apparent at a dose of 0.02 mg/kg.

3 ceive levosimendan (in a continuous infusion at a dose of 0.025 to 0.2 mug per kilogram of body weigh

4 single subcutaneous injection of fitusiran (at a dose of 0.03 mg per kilogram of body weight) or pla

5 At a dose of 0.05 mg/kg, ANG2002 effectively reversed pa

6 receive a blinded infusion of levosimendan (at a dose of 0.05 to 0.2 mug per kilogram of body weight

7 s began to decline; it was then administered at a dose of 0.1 mg once or twice daily.

8 IU dose via intravenous infusion of ins-asp at a dose of 0.12 IU/kg/24 h (n = 10), we obtained essen

9 ulmonary-artery shunt to receive clopidogrel at a dose of 0.2 mg per kilogram of body weight per day

10 to receive either intravenous levosimendan (at a dose of 0.2 mug per kilogram of body weight per min

11 , or 0.075 mg per kilogram) or once monthly (at a dose of 0.225, 0.45, 0.9, or 1.8 mg per kilogram or

12 e of 0.5 mg (2.1% vs. 7.7%, P=0.001) but not at a dose of 0.25 mg (2.1% vs. 5.3%, P=0.08).

13 n at a dose of 300 mg per day or pramipexole at a dose of 0.25 mg or 0.5 mg per day or 12 weeks of pl

14 f 1.25 mg (218 participants), or ranibizumab at a dose of 0.3 mg (218 participants).

15 Administration of TKM-130803 at a dose of 0.3 mg/kg/d by intravenous infusion to adul

16 x normalized hemostasis upon vascular injury at a dose of 0.3 nmol/kg compared with 300 nmol/kg for F

17 lower with pregabalin than with pramipexole at a dose of 0.5 mg (2.1% vs. 7.7%, P=0.001) but not at

18 %, and 78% of patients receiving tofacitinib at a dose of 0.5 mg (P=0.39), 3 mg (P=0.55), 10 mg (P=0.

19 %, and 41% of patients receiving tofacitinib at a dose of 0.5 mg (P=0.76), 3 mg (P=0.01), 10 mg (P<0.

20 igned, in a 1:1:1 ratio, to receive ozanimod at a dose of 0.5 mg or 1 mg or placebo daily for up to 3

21 domly assigned to receive either colchicine (at a dose of 0.5 mg twice daily for 3 months for patient

22 ere randomly assigned to receive tofacitinib at a dose of 0.5 mg, 3 mg, 10 mg, or 15 mg or placebo tw

23 icacy studies, surotomycin protected animals at a dose of 0.5 mg/kg, PO.

24 At a dose of 0.55 displacements per atom (dpa), the pair

25 This ameliorative effect occurred at a dose of 0.5mg/kg/d (mkd), translating to a human-eq

26 deoxycholate (amphotericin) (219 patients), at a dose of 0.7 to 1.0 mg per kilogram of body weight p

27 135 or 175 mg per square meter or topotecan at a dose of 0.75 mg per square meter on days 1 to 3, pl

28 effects of rovalpituzumab tesirine occurred at a dose of 0.8 mg/kg every 3 weeks, including grade 4

29 xidative DNA damage (46%) in the colon cells at a dose of 1 mg of freeze-dried EDB powder/ml.

30 cceptable level of adverse events (nivolumab at a dose of 1 mg per kilogram of body weight and ipilim

31 sebelipase alfa (administered intravenously at a dose of 1 mg per kilogram of body weight every othe

32 All patients received amphotericin B at a dose of 1 mg per kilogram of body weight per day; p

33 eated advanced melanoma to receive nivolumab at a dose of 1 mg per kilogram of body weight plus ipili

34 owed that cKK-E12 was well tolerated in rats at a dose of 1 mg/kg (over 100-fold higher than the ED50

35 misation system to oral daily mercaptopurine at a dose of 1 mg/kg bodyweight rounded to the nearest 2

36 romethylbenzoyl)-1, 3 cyclohexandione (NTBC) at a dose of 1 mg/kg per day initially after birth.

37 T4 group received an intramuscular injection at a dose of 1 x 109 50% tissue culture infectious dose

38 assigned to receive intravenous ustekinumab (at a dose of 1, 3, or 6 mg per kilogram of body weight)

39 MARV/Ang-MA in SCID mice, and i.p. infection at a dose of 1,000x LD50 resulted in death between 6 and

40 Paratyphi A at a dose of 1-5 x 103 CFU was well tolerated and associ

41 At a dose of 1.0 mg per kilogram, ALN-TTR01 suppressed t

42 ith in vivo gene silencing potencies of >90% at a dose of 1.0 mg/kg in mice were discovered.

43 ts with hyperkalemia to receive either ZS-9 (at a dose of 1.25 g, 2.5 g, 5 g, or 10 g) or placebo thr

44 se of 2.0 mg (224 participants), bevacizumab at a dose of 1.25 mg (218 participants), or ranibizumab

45 n, but replacing vincristine with bortezomib at a dose of 1.3 mg per square meter of body-surface are

46 (CTL019 chimeric antigen receptor T cells), at a dose of 1.4x10(6) to 1.2x10(7) CTL019 cells per kil

47 Treatment with vincristine at a dose of 1.5 or 2.0 mg/m2.

48 iol unacceptable to receive obeticholic acid at a dose of 10 mg (the 10-mg group), obeticholic acid a

49 py with diet alone or diet plus atorvastatin at a dose of 10 mg daily, atorvastatin at a dose of 80 m

50 atin at a dose of 80 mg daily plus ezetimibe at a dose of 10 mg daily, for a run-in period of 4 to 12

51 donepezil continuously for at least 3 months at a dose of 10 mg for at least the previous 6 weeks and

52 urface area to receive either empagliflozin (at a dose of 10 mg or 25 mg) or placebo once daily.

53 Escitalopram was given at a dose of 10 mg per day for 3 weeks and 20 mg per day

54 lowed by a maintenance regimen (lenalidomide at a dose of 10 mg per day on days 1 to 21 of each 28-da

55 at intermediate risk to receive rosuvastatin at a dose of 10 mg per day or placebo.

56 Treatment with rosuvastatin at a dose of 10 mg per day resulted in a significantly l

57 randomly assigned them to receive ipilimumab at a dose of 10 mg per kilogram (475 patients) or placeb

58 oma, this phase 3 trial evaluated ipilimumab at a dose of 10 mg per kilogram in patients who had unde

59 Pembrolizumab was administered intravenously at a dose of 10 mg per kilogram of body weight every 14

60 We administered lambrolizumab intravenously at a dose of 10 mg per kilogram of body weight every 2 o

61 a in a 1:1:1 ratio to receive pembrolizumab (at a dose of 10 mg per kilogram of body weight) every 2

62 for high-risk stage III melanoma, ipilimumab at a dose of 10 mg per kilogram resulted in significantl

63 :1 ratio to receive intravenous secukinumab (at a dose of 10 mg per kilogram) at weeks 0, 2, and 4, f

64 d, double-blind study, we compared apixaban (at a dose of 10 mg twice daily for 7 days, followed by 5

65 a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommen

66 Avelumab was given intravenously at a dose of 10 mg/kg every 2 weeks.

67 off and intravenous trebananib once per week at a dose of 10 mg/kg in cohort A or 15 mg/kg in cohort

68 Rifampin at a dose of 10 mg/kg was introduced in 1971 based on ph

69 rted during induction (ipilimumab or placebo at a dose of 10 mg/kg, administered as one single dose a

70 treatment from 3 weeks of age for 15 months at a dose of 10 mg/kg/day stabilized myofiber membranes,

71 a-analysis suggests that the use of oral BPs at a dose of 10 or more prescriptions or 1 or more years

72 andomly assigned them to receive lisinopril (at a dose of 10 to 40 mg per day) or placebo.

73 2010 [H3N2 variant]) to ferrets intranasally at a dose of 10(6) 50% tissue culture infective doses in

74 ion in the upper and lower respiratory tract at a dose of 10(6) PFU of vaccine.

75 group, n = 365) or B. animalis subsp. lactis at a dose of 10(9) colony-forming units/d (intervention

76 d venous thromboembolism to receive aspirin, at a dose of 100 mg daily, or placebo for up to 4 years.

77 ebo group crossed over to receive guselkumab at a dose of 100 mg every 8 weeks.

78 Methods We provided losartan (at a dose of 100 mg per day) to patients with type 2 dia

79 in group 2 concurrently received flucytosine at a dose of 100 mg per kilogram per day for 2 weeks, an

80 resistant tuberculosis to receive delamanid, at a dose of 100 mg twice daily (161 patients) or 200 mg

81 daily (high-dose posaconazole), posaconazole at a dose of 100 mg twice daily (low-dose posaconazole),

82 cted an open-label study of oral midostaurin at a dose of 100 mg twice daily in 116 patients, of whom

83 Treatment with oral CMX001 at a dose of 100 mg twice weekly significantly reduced t

84 tly lower among patients who received CMX001 at a dose of 100 mg twice weekly than among patients who

85 Mepolizumab at a dose of 100 mg was associated with a lower annual r

86 just before surgery and continued it daily (at a dose of 100 mg) for 30 days in the initiation strat

87 lucocorticoid-sparing effect of mepolizumab (at a dose of 100 mg) with that of placebo administered s

88 2 flinching in the mouse formalin test even at a dose of 100 mpk PO due to insufficient dorsal root

89 y inhaled combination of fluticasone furoate at a dose of 100 mug and vilanterol at a dose of 25 mug

90 NO production peaked in mIMCD cells at a dose of 100 nm insulin with simultaneously increase

91 Patients were treated with acalabrutinib at a dose of 100 to 400 mg once daily in the dose-escala

92 Obinutuzumab was given at a dose of 1000 mg (100 mg IV day 1, 900 mg day 2, 100

93 tched placebo every 3 weeks) or dacarbazine (at a dose of 1000 mg per square meter of body-surface ar

94 17 years of age were treated with metformin (at a dose of 1000 mg twice daily) to attain a glycated h

95 se of 16 mg per day plus hydrochlorothiazide at a dose of 12.5 mg per day or placebo.

96 se of 16 mg per day plus hydrochlorothiazide at a dose of 12.5 mg per day was not associated with a l

97 known in the United States as Depot], Ipsen) at a dose of 120 mg (101 patients) or placebo (103 patie

98 daily letermovir dose of 60 mg (P=0.32), 32% at a dose of 120 mg (P=0.01), and 29% at a dose of 240 m

99 infection to one of five groups: faldaprevir at a dose of 120 mg once daily and deleobuvir at a dose

100 ID28W, or TID40W, respectively); faldaprevir at a dose of 120 mg once daily and deleobuvir at a dose

101 virin, for 28 weeks (BID28W); or faldaprevir at a dose of 120 mg once daily and deleobuvir at a dose

102 meter of body-surface area, plus paclitaxel at a dose of 135 or 175 mg per square meter or topotecan

103 m (3 x 10(10)/g), Acetobacter (1 x 10(6)/g)) at a dose of 140 mg/kg (1.4 x 10(10) CFU/kg).

104 to chemotherapy with or without bevacizumab at a dose of 15 mg per kilogram of body weight.

105 ous intravenous infusion of either ularitide at a dose of 15 ng per kilogram of body weight per minut

106 pe diet for 5 weeks with peanut skin extract at a dose of 150 and 300 mg/kg body weight.

107 nce daily for 1 month followed by dalteparin at a dose of 150 IU per kilogram once daily (dalteparin

108 iandrogen therapy (24 months of bicalutamide at a dose of 150 mg daily) or daily placebo tablets duri

109 daclizumab HYP, administered subcutaneously at a dose of 150 mg every 4 weeks, with interferon beta-

110 up were switched to subcutaneous secukinumab at a dose of 150 mg or 75 mg at week 16 or 24, depending

111 domly reassigned to subcutaneous secukinumab at a dose of 150 mg or 75 mg.

112 ndomly assigned to receive either pregabalin at a dose of 150 mg per day that was adjusted to a maxim

113 for preterm preeclampsia to receive aspirin, at a dose of 150 mg per day, or placebo from 11 to 14 we

114 r V600K mutations to receive oral dabrafenib at a dose of 150 mg twice daily plus trametinib at a dos

115 d, randomized trials, we compared dabigatran at a dose of 150 mg twice daily with warfarin (active-co

116 ily (low-dose posaconazole), or benznidazole at a dose of 150 mg twice daily; all the study drugs wer

117 to receive rituximab and either idelalisib (at a dose of 150 mg) or placebo twice daily.

118 the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or pla

119 Therapy with candesartan at a dose of 16 mg per day plus hydrochlorothiazide at a

120 scular disease to receive either candesartan at a dose of 16 mg per day plus hydrochlorothiazide at a

121 717 patients to receive either enzalutamide (at a dose of 160 mg) or placebo once daily.

122 ase to receive either once-daily darapladib (at a dose of 160 mg) or placebo.

123 ratio, to receive subcutaneous tocilizumab (at a dose of 162 mg) weekly or every other week, combine

124 ither paclitaxel, administered intravenously at a dose of 175 mg per square meter of body-surface are

125 square meter on days 1 to 3, plus paclitaxel at a dose of 175 mg per square meter on day 1.

126 cy similar to those of tiotropium HandiHaler at a dose of 18 mug in patients with COPD.

127 ved triple therapy consisting of tiotropium (at a dose of 18 mug once daily), salmeterol (50 mug twic

128 amuscularly to dogs in a sesame oil solution at a dose of 1mg-eq. nalmefene/kg.

129 a dose of 150 mg twice daily plus trametinib at a dose of 2 mg once daily (combination therapy, 438 p

130 ous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly.

131 therapy to receive pembrolizumab (anti-PD-1) at a dose of 2 mg per kilogram of body weight every 3 we

132 The results suggest that pembrolizumab at a dose of 2 mg/kg or 10 mg/kg every 3 weeks might be

133 t of lipopolysaccharide (LPS) administration at a dose of 2 ng/kg of body weight on motivation in 21

134 the patients in a 1:1:1 ratio to baricitinib at a dose of 2 or 4 mg daily or placebo for 24 weeks.

135 At a dose of 2 x 10(2) PFU, one parental virus was absen

136 center to receive intravitreous aflibercept at a dose of 2.0 mg (224 participants), bevacizumab at a

137 of cyclosporine (administered intravenously at a dose of 2.5 mg per kilogram of body weight) or matc

138 idence interval [CI], 0.84 to 1.09; Respimat at a dose of 2.5 mug vs. HandiHaler: hazard ratio, 1.00;

139 duction phase, lenalidomide was administered at a dose of 20 mg daily on days 1 through 21 of every 2

140 rgery to receive perioperative rosuvastatin (at a dose of 20 mg daily) or placebo.

141 in a 2:1 ratio to receive either adalimumab (at a dose of 20 mg or 40 mg, according to body weight) o

142 per day on days 1 to 21, plus dexamethasone at a dose of 20 mg per day on days 1 to 4 and days 12 to

143 to receive either cannabidiol oral solution at a dose of 20 mg per kilogram of body weight per day o

144 eive one of four treatments: oxantel pamoate at a dose of 20 mg per kilogram of body weight, plus 400

145 Decitabine was administered at a dose of 20 mg per square meter of body-surface area

146 3) every 28 days, with weekly dexamethasone at a dose of 20 mg.

147 With ethinyl estradiol at a dose of 20 mug, the corresponding relative risks ac

148 ly and dexamethasone was given once per week at a dose of 20 or 40 mg.

149 Selumetinib was administered twice daily at a dose of 20 to 30 mg per square meter of body-surfac

150 (edoxaban group) or subcutaneous dalteparin at a dose of 200 IU per kilogram of body weight once dai

151 lizumab, a humanized PD-1-blocking antibody, at a dose of 200 mg every 3 weeks in relapsed and transf

152 randomized, phase 3 study compared melphalan at a dose of 200 mg per square meter of body-surface are

153 r (17%) and two (9%) patients, respectively, at a dose of 200 mg twice a day, and in six (40%) and fo

154 INTERPRETATION: AZD3759 at a dose of 200 mg twice daily showed a tolerable safet

155 ion of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose

156 iarrhea was dose-limiting in this population at a dose of 200 mg twice weekly.

157 Patients started taking aspirin (at a dose of 200 mg) or placebo just before surgery and

158 ), 32% at a dose of 120 mg (P=0.01), and 29% at a dose of 240 mg (P=0.007).

159 t difference in the comparison of letermovir at a dose of 240 mg per day with placebo (P=0.002).

160 BG-12 at a dose of 240 mg twice daily, BG-12 at a dose of 240 mg three times daily, or placebo.

161 were randomly assigned to receive oral BG-12 at a dose of 240 mg twice daily, BG-12 at a dose of 240

162 gated the efficacy and safety of oral BG-12, at a dose of 240 mg two or three times daily, as compare

163 nt improvement in FEV1 compared with placebo at a dose of 25 mg once daily (P = 0.028).

164 received an induction regimen (lenalidomide at a dose of 25 mg per day on days 1 to 21, plus dexamet

165 furoate at a dose of 100 mug and vilanterol at a dose of 25 mug (the fluticasone furoate-vilanterol

166 ebo in either a single-ascending-dose phase (at a dose of 25, 100, 300, 500, or 800 mg) or a multiple

167 7.5 +/- 0.7 days when injected daily 6 times at a dose of 26 mug/kg starting from the second day afte

168 f 3 mg per kilogram every 2 weeks; nivolumab at a dose of 3 mg per kilogram every 2 weeks plus placeb

169 weeks for four doses, followed by nivolumab at a dose of 3 mg per kilogram every 2 weeks; nivolumab

170 per kilogram of body weight plus ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four do

171 am every 2 weeks plus placebo; or ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four do

172 assigned 272 patients to receive nivolumab, at a dose of 3 mg per kilogram of body weight every 2 we

173 ed doublet chemotherapy to receive nivolumab at a dose of 3 mg per kilogram of body weight every 2 we

174 ithout a BRAF mutation to receive nivolumab (at a dose of 3 mg per kilogram of body weight every 2 we

175 eceive nivolumab (administered intravenously at a dose of 3 mg per kilogram of body weight once every

176 ady been heavily treated received nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 w

177 trial showed that propranolol was effective at a dose of 3 mg per kilogram per day for 6 months in t

178 g per kilogram of body weight and ipilimumab at a dose of 3 mg per kilogram), 53% of patients had an

179 r volume to one-fifth of the starting volume at a dose of 3 mg/kg administered ip, bid, days 1-9.

180 vo efficacy by inhibition of REM sleep state at a dose of 3 mg/kg po in the rat sleep-wake EEG paradi

181 At a dose of 3 mg/kg, compound 1 significantly reduced r

182 enous shunt thrombosis model by 57.91%, both at a dose of 3 mg/kg.

183 ACH-11 did not prolong bleeding time in mice at a dose of 3 mg/kg.

184 s received induction therapy with ipilimumab at a dose of 3 or 10 mg per kilogram of body weight ever

185 eters) of more than 35 to receive metformin, at a dose of 3.0 g per day, or placebo (225 women in eac

186 daily subcutaneous injections of liraglutide at a dose of 3.0 mg (2487 patients) or placebo (1244 pat

187 al, we assessed the effects of benralizumab (at a dose of 30 mg administered subcutaneously either ev

188 safety, and adverse-event profile of KAE609, at a dose of 30 mg per day for 3 days, in two sequential

189 epeatable [LAR] administered intramuscularly at a dose of 30 mg) ((177)Lu-Dotatate group) or octreoti

190 rferon beta-1a, administered intramuscularly at a dose of 30 mug once weekly, for up to 144 weeks.

191 10 mg twice daily, 2340 to receive aliskiren at a dose of 300 mg once daily, and 2340 to receive both

192 e FIXTURE study) to subcutaneous secukinumab at a dose of 300 mg or 150 mg (administered once weekly

193 Lanadelumab at a dose of 300 mg or 400 mg reduced cleavage of high-m

194 eceive 52 weeks of treatment with pregabalin at a dose of 300 mg per day or pramipexole at a dose of

195 (40%) and four (27%) patients, respectively, at a dose of 300 mg twice a day.

196 74 patients (cohort 1) received vedolizumab (at a dose of 300 mg) or placebo intravenously at weeks 0

197 d, with a procognitive signal in AD patients at a dose of 35 mg/d superior to the other doses tested

198 Patients and Methods We delivered PMRT at a dose of 36.63 Gy in 11 fractions of 3.33 Gy over 11

199 igated whether rituximab maintenance therapy at a dose of 375 mg per square meter of body-surface are

200 etion, and circulating insulin within 7 days at a dose of 4 (mg/kg bw)/day.

201 erapy alone or with zoledronate administered at a dose of 4 mg for 19 doses over 5 years.

202 the first fraction of radiotherapy each week at a dose of 4 x 10(11) particle units by using either a

203 reated participants.In this pilot trial, KCl at a dose of 40 mEq/d did not increase serum potassium s

204 assigned to receive subcutaneous enoxaparin (at a dose of 40 mg once daily) for 10+/-4 days plus oral

205 groups; all four groups received sofosbuvir (at a dose of 400 mg once daily) plus ribavirin for 12 we

206 eptember 2012 to once-daily oral fedratinib, at a dose of 400 mg or 500 mg, or placebo, for at least

207 e of 60 mg orally once daily plus sofosbuvir at a dose of 400 mg orally once daily, with or without r

208 te cancer were treated with olaparib tablets at a dose of 400 mg twice a day.

209 ly assigned patients to receive posaconazole at a dose of 400 mg twice daily (high-dose posaconazole)

210 in group 3 concurrently received fluconazole at a dose of 400 mg twice daily for 2 weeks.

211 reatment with ebselen was safe and effective at a dose of 400 mg twice daily in preventing a noise-in

212 o or solanezumab (administered intravenously at a dose of 400 mg) every 4 weeks for 18 months.

213 24 weeks or subcutaneous interferon beta-1a at a dose of 44 mug three times weekly for 96 weeks.

214 stain the desired level of target engagement at a dose of 45 mg qd.

215 90 mg per week: three patients were started at a dose of 450 mg per week, three at 360 mg per week,

216 up to 13 weeks with oral ulipristal acetate at a dose of 5 mg per day (96 women) or 10 mg per day (9

217 of 10 mg (the 10-mg group), obeticholic acid at a dose of 5 mg with adjustment to 10 mg if applicable

218 n serum from mice injected intraperitoneally at a dose of 5 mg/kg for each protein.

219 Bevacizumab was applied at a dose of 5 mg/kg once every three weeks at least thr

220 n vivo antitumor and antivascular activities at a dose of 5 mg/kg without obvious toxicity, whereas 1

221 Tiotropium Respimat at a dose of 5 mug or 2.5 mug had a safety profile and e

222 isk of death (noninferiority study, Respimat at a dose of 5 mug or 2.5 mug vs. HandiHaler) and the ri

223 PD exacerbation (superiority study, Respimat at a dose of 5 mug vs. HandiHaler).

224 with respect to the risk of death (Respimat at a dose of 5 mug vs. HandiHaler: hazard ratio, 0.96; 9

225 the risk of the first exacerbation (Respimat at a dose of 5 mug vs. HandiHaler: hazard ratio, 0.98; 9

226 Tiotropium delivered at a dose of 5 mug with the Respimat inhaler showed effi

227 patients were assigned to receive enalapril at a dose of 5 or 10 mg twice daily, 2340 to receive ali

228 elope A insert [Ad35.Env], both administered at a dose of 5 x 1010 viral particles) in homologous and

229 After FUS, DOX was administered at a dose of 5.67mg/kg.

230 io, to receive six injections of radium-223 (at a dose of 50 kBq per kilogram of body weight intraven

231 o, or (in the FIXTURE study only) etanercept at a dose of 50 mg (administered twice weekly for 12 wee

232 Chemotherapy consisted of cisplatin at a dose of 50 mg per square meter of body-surface area

233 pants were randomly assigned to dolutegravir at a dose of 50 mg plus abacavir-lamivudine once daily (

234 Twenty-five patients received eltrombopag at a dose of 50 mg, which could be increased, as needed,

235 rated with low discontinuation rates (19.6%) at a dose of 50 mg/d, whereas the dose of 125 mg/d had h

236 animalis VKL, Bifidobacterium animalis VKB) at a dose of 50 mg/kg (5 x 10(9) CFU/kg) (g) (intragastr

237 intravenous injection of [Thr28, Nle31]-CCK at a dose of 50 ng/kg significantly increased plasma tri

238 T790M-positive disease received rociletinib at a dose of 500 mg twice daily, 625 mg twice daily, or

239 ed clinical trial demonstrated that naproxen at a dose of 500 mg twice per day is effective in reduci

240 blingual tablet containing placebo or STG320 at a dose of 500IR, 300IR, or 100IR (IR, index of reacti

241 as given orally or via nasogastric tube once at a dose of 540,000 IU followed by monthly maintenance

242 ives were evaluated in dogs and in minipigs, at a dose of 5mg-eq. nalmefene/kg and plasma nalmefene c

243 factor IX Padua (factor IX-R338L) transgene at a dose of 5x10(11) vector genomes per kilogram of bod

244 PDT was applied with verteporfin at a dose of 6 mg/m(2) body surface area and a 689 nm di

245 Vinblastine was administered once per week at a dose of 6 mg/m(2) intravenously over a period of 70

246 lucose and insulin at 45 and 60min, but only at a dose of 6.0g.

247 (113 patients) administered intramuscularly at a dose of 60 mg every 4 weeks (control group).

248 or at least 5 days followed by oral edoxaban at a dose of 60 mg once daily (edoxaban group) or subcut

249 tially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g.

250 cted with HCV genotype 2 or 3 to daclatasvir at a dose of 60 mg orally once daily plus sofosbuvir at

251 ive either an enteral emulsion providing DHA at a dose of 60 mg per kilogram of body weight per day o

252 Enteral DHA supplementation at a dose of 60 mg per kilogram per day did not result i

253 Patients received oral letermovir (at a dose of 60, 120, or 240 mg per day, or matching pla

254 e to receive the CETP inhibitor dalcetrapib, at a dose of 600 mg daily, or placebo, in addition to th

255 sclerosis to receive intravenous ocrelizumab at a dose of 600 mg every 24 weeks or subcutaneous inter

256 ay, or itraconazole capsules (221 patients), at a dose of 600 mg per day for 3 days, followed by 400

257 t a dose of 120 mg once daily and deleobuvir at a dose of 600 mg three times daily, plus ribavirin, f

258 t a dose of 120 mg once daily and deleobuvir at a dose of 600 mg three times daily, without ribavirin

259 t a dose of 120 mg once daily and deleobuvir at a dose of 600 mg twice daily, plus ribavirin, for 28

260 al range to receive subcutaneous pasireotide at a dose of 600 mug (82 patients) or 900 mug (80 patien

261 dy do not support that choline, administered at a dose of 625 mg/d for 6 wk, is an effective interven

262 At a dose of 69 kGy the uptake of hydrogen by metallic c

263 ceive either (177)Lu-Dotatate (116 patients) at a dose of 7.4 GBq every 8 weeks (four intravenous inf

264 Animals were x-ray-irradiated at a dose of 7.5 Gy with 1 of 3 radiation schemes-whole-

265 patients with type 1 diabetes, oral insulin at a dose of 7.5 mg/d, compared with placebo, did not de

266 Moxifloxacin is currently recommended at a dose of 7.5-10 mg/kg for children with multidrug-re

267 The use of tezepelumab at a dose of 70 mg every 4 weeks (low dose; 145 patients

268 a subcutaneous injection of either erenumab, at a dose of 70 mg or 140 mg, or placebo monthly for 6 m

269 to receive subcutaneous romosozumab monthly (at a dose of 70 mg, 140 mg, or 210 mg) or every 3 months

270 l subjects received the hepatitis A vaccine, at a dose of 720 enzyme-linked immunosorbent assay (ELIS

271 ts who had IBS with diarrhea to eluxadoline (at a dose of 75 mg or 100 mg) or placebo twice daily for

272 of body weight every 2 weeks, or docetaxel, at a dose of 75 mg per square meter of body-surface area

273 cancer to receive either ADT plus docetaxel (at a dose of 75 mg per square meter of body-surface area

274 am of body weight every 2 weeks or docetaxel at a dose of 75 mg per square meter of body-surface area

275 Docetaxel was given at a dose of 75 mg/m(2) by intravenous infusion every 3

276 interleukin-6 receptor antibody tocilizumab (at a dose of 8 mg per kilogram of body weight if the wei

277 st line pharmacotherapy for women with IBS-C at a dose of 8 mug BID.

278 in at a dose of 80 mg daily, or atorvastatin at a dose of 80 mg daily plus ezetimibe at a dose of 10

279 tatin at a dose of 10 mg daily, atorvastatin at a dose of 80 mg daily, or atorvastatin at a dose of 8

280 lacebo for 10+/-4 days plus oral betrixaban (at a dose of 80 mg once daily) for 35 to 42 days.

281 ious 48 hours to receive enteral simvastatin at a dose of 80 mg or placebo once daily for a maximum o

282 ix cycles or paclitaxel, administered weekly at a dose of 80 mg per square meter, plus carboplatin (A

283 ne course of TMZ (3 d exposure and 4 d rest) at a dose of 80 mg/kg resulted in substantial reduction

284 h 4 week cycle plus paclitaxel intravenously at a dose of 80 mg/m(2) on days 1, 8, and 15 of each 4 w

285 red the synthetic sex hormone danazol orally at a dose of 800 mg per day for a total of 24 months.

286 al were incorporated into feed in spore form at a dose of 8x10(7) CFU/g and fed to channel catfish fo

287 Intracameral injection of cefuroxime sodium at a dose of 9 mg/0.1 mL was associated with transient m

288 All formulations were administered as bolus at a dose of 9 mg/kg.

289 ucted an open-label trial with PfSPZ Vaccine at a dose of 9.0 x 10(5) PfSPZ administered i.v. three t

290 patients who received free-base rociletinib at a dose of 900 mg twice daily or the HBr form at any d

291 e-group, multicenter studies of vemurafenib (at a dose of 960 mg twice daily)--one in Italy and one i

292 Supplementing human milk with DHA at a dose of approximately 1% of total fatty acids given

293 g patients receiving intravenous ustekinumab at a dose of either 130 mg or approximately 6 mg per kil

294 and 4, followed by subcutaneous secukinumab at a dose of either 150 mg or 75 mg every 4 weeks, or pl

295 signed 495 patients receiving pembrolizumab (at a dose of either 2 mg or 10 mg per kilogram of body w

296 Patients received pembrolizumab at a dose of either 2 mg/kg of bodyweight or 10 mg/kg ev

297 It is possible that epicatechin at a dose of >1.6 mg/kg body weight, alone or in concert

298 ting toxic events were noted in phase 1: one at a dose of ixazomib of 2.97 mg/m(2) and three at 3.95

299 assigned patients to placebo or ivabradine, at a dose of up to 10 mg twice daily, with the dose adju

300 HES 130/0.42 (Tetraspan) or Ringer's acetate at a dose of up to 33 ml per kilogram of ideal body weig